ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
EN
07/10/2020

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Thijs Berkelder
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
SZG SALZGITTER AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
ALCLS CELLECTIS SA
KER KERING SA
01913 PRADA S.P.A.
KRN KRONES AG
MLP MLP SE
CCC CCC SA
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TRE TECNICAS REUNIDAS SA
ZGN ERMENEGILDO ZEGNA NV
DEME DEME GROUP NV
STM STABILUS SE
11/10/25 November 10, 2025 1 EN
Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Thijs Berkelder
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
SZG SALZGITTER AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
ALCLS CELLECTIS SA
KER KERING SA
01913 PRADA S.P.A.
KRN KRONES AG
MLP MLP SE
CCC CCC SA
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
TRE TECNICAS REUNIDAS SA
ZGN ERMENEGILDO ZEGNA NV
DEME DEME GROUP NV
STM STABILUS SE
11/10/25 November 10, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
11/10/25 November 10, 2025 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
11/10/25 November 10, 2025 1 FR
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Third Quarter 2025 Financial Results and Provides Bu...

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) ORR of 86% and 57% CR rate (n=7)Development update to be pre...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch